Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Reshaping Dosage Forms

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Frontrunners in Bispecific Antibodies

Topic

Articles

CMC Biologics and OnoSynergy form an agreement from cell-line development.

CMC Biologics and OncoSynergy Form Pact

Pfizer appoints management changes to take effect in 2014.

Pfizer Appoints Head of Vaccines

Operator training, preventive maintenance, and regularly scheduled calibration help prevent the manufacture of off-weight tablets.

Preventing Off-weight Tablets

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

Biogen and Samsung Bioepis, a joint venture between Samsung Biologics and Biogen Idec, advance plans for anti-TNF biosimilar product candidates.

Biogen Idec, Samsung Bioepis Target Anti-TNF Biosimilars in Europe

BioWa and Lonza have entered into a licensing agreement with MedImmune for cell line technology.

Lonza, BioWa Sign Licensing Agreement

Teva Pharmaceutical Industries releases a financial outlook for 2014 based on two possible scenarios concerning its multiple-sclerosis drug Copaxone (glatiramer acetate).

Teva Releases Financial Guidance Dependent on Copaxone Generic Competition

Alvotech plans investment in biosimilars portfolio and manufacturing facility.

Alvotech Plans Multimillion Biosimilars Investment

Jill E. Sackman, D.V.M., PhD, senior consultant at Numerof & Associates, Inc. discusses the market forces impacting biopharmaceutical manufacturing

The Impact of Biosimilars on the Innovator Market

Excipients for lowering formulation costs and improving lipid-based formulations and the use of melt-spray-congeal microsphere sachet technology for targeted controlled release attract attention at the 2013 American Association of Pharmaceutical Scientists Annual Meeting.

New Solid Dose Technologies Highlighted at 2013 AAPS Annual Meeting & Expo

Sean Milmo is a freelance writer based in Essex, UK.

The European Union is strengthening its pioneering role in the regulation of biosimilars by further developing the basic rules for determining the levels of compatibility for this group of drugs. There are, however, some key issues that are not easy to resolve, as evident in a recent workshop on biosimilars organized by the European Medicines Agency (EMA).